Grant: Project Grant

In the last decade, significant advances have been made in the field of prostate cancer (PCa), with many innovative drugs being approved by Health Canada, initially for advanced stages, and evolving to earlier stages of this disease. The complexity, the costs of management and the decision-making process in PCa incurred by the explosion of these new drugs are substantial. Although patients benefit from greater survival, the cost associated with these treatments put an enormous pressure on the healthcare system. Due to economic considerations and/or uncertainties related to the clinical trials context, many of these innovative drugs are not accessible on a timely meaner or optimally, or not accessible at all, to patients that might benefit from them. The main objective of this research project is to create timely real-world evidence and economic evaluations for prostate cancer in order to overcome the uncertainties related to the clinical trials context and/or need for economic evaluation of newly approved treatments and/or new indications. This research project will improve clinical decisions, healthcare optimization, influence health policy decisions in prostate cancer.